drugset
drugset / Trial / NCT01425879

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

NCT01425879 ↗

Phase 2 Completed 8 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.

Timeline

Start
2011-04
Primary completion
2013-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-2206 Small molecule — Oral

Indications

adult hepatocellular carcinoma distal biliary tract carcinoma gallbladder carcinoma